"GLP-1 companion" is a label category that the supplement industry created, not a medical one. No GLP-1 drug label tells people to take a supplement. What does exist is a 2025 joint advisory from four obesity and nutrition societies that names which nutrients may need attention when appetite falls, a small trial record on whether deficiencies actually happen, and a growing shelf of products sold to people on Ozempic, Wegovy, Mounjaro and Zepbound.
This page reads those three things side by side. It is about products positioned to be taken alongside a GLP-1 drug. Supplements that claim to raise the body's own GLP-1, such as berberine, are a different claim with a different trial record, set out on GLP-1 supplements.
What the joint advisory names
Nutritional priorities to support GLP-1 therapy for obesity was published in 2025 by the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society (Mozaffarian and 17 co-authors; the same text appeared in four journals, and a correction followed in 2026). Its starting point is arithmetic: the drugs cut calorie intake by 16–39% in the studies it cites, and intake below about 1,200 kcal a day for women or 1,800 for men makes it harder to get enough vitamins and minerals from food.
What it says about supplements, quoted:
| Topic | The advisory's wording |
|---|---|
| Micronutrients | "Dietary supplements can be proactively considered for at-risk nutrients, such as vitamin D, calcium, and B12, tailored to each person's needs." |
| Protein | "Some individuals can meet protein targets by supplementing with high-protein shakes, bars, and other fortified products." |
| Constipation | If dietary strategies are insufficient, "other therapies include daily magnesium supplementation"; "Fiber supplements or capsules and Polyethylene Glycol 3350 may also be beneficial." |
| Overall | Lifestyle support should include "micronutrient or protein supplementation as needed." |
Three things stand out. Every recommendation is conditional — "can be considered", "as needed", "tailored". The named micronutrients are three, not a long list. And the advisory pairs them with assessment: it lists fatigue beyond expected levels, excessive hair loss, skin flaking or itching, muscle weakness, poor wound healing and unusual bruising as signs of frank deficiency, which are clinical findings, not shopping prompts. The protein targets it discusses are set out, with the trials behind them, on protein and GLP-1s.
What the studies found about deficiencies
The worry is plausible; the measured record is small.
- Randomised trials. A 2026 systematic review (de Paulo and colleagues, Diabetes, Obesity and Metabolism, PMID 42037117) gathered 16 trials with 7,096 participants given a GLP-1 or dual GIP/GLP-1 drug alongside lifestyle or dietary guidance. Gastrointestinal symptoms were consistent; lean mass loss was generally in proportion to total weight lost; none of the trials reported clinically relevant nutritional deficiencies, and none directly assessed bone health. Most trials were not designed to look for deficiencies, so "none reported" is not the same as "none occurred".
- Narrative evidence. A 2026 review in Obesity Pillars (Simancas-Racines and colleagues, PMID 42382663) pulled together cohort, trial, pharmacovigilance and mechanistic data. It names iron, vitamin B12, vitamin D, calcium, magnesium and zinc as the most relevant signals, with thiamine, folate, vitamin A and potassium in particular contexts, and states that "most abnormalities reported to date are subclinical or indirect". It identifies prior bariatric surgery, gastrointestinal disorders, poor baseline diet, older age and prolonged nausea and vomiting as the situations where consequences are more likely, and calls for prospective studies to measure how often any of this happens.
- The serious end. A 2026 systematic review of case reports (Bidesie and Oudman, Obesity, PMID 42399213) found six published cases of Wernicke's encephalopathy — brain injury from thiamine (vitamin B1) deficiency — after semaglutide for obesity. All six patients had prolonged gastrointestinal symptoms and substantial weight loss first; outcomes in several were poor, including Korsakoff syndrome and death. Six cases cannot give a rate. What they show is the pattern that matters: the danger sits with people who cannot keep food down for a long time, which is a reason to contact a prescriber, not a reason for everyone to buy thiamine.
What a "companion" label actually contains
The NIH Dietary Supplement Label Database (DSLD) holds labels submitted from the market. Searched on 19 November 2026 for products with "GLP" in the name, it returned ten labels entered in 2025 (plus three older, unrelated Reishi entries). Only one is named as a companion: Codeage GLP-Harmony Companion+ (DSLD 333410, entered 24 July 2025).
Its Supplement Facts panel, per serving of two capsules:
| Ingredient | Amount |
|---|---|
| Lion's mane mushroom fruiting body extract | 500 mg |
| Palmitoylethanolamide | 300 mg |
| Bovine colostrum | 200 mg |
| Shilajit resin extract | 100 mg |
| Black elder fruit extract | 100 mg |
| Blueberry powder | 50 mg |
| Citrus bioflavonoids | 50 mg |
| Broccoli seed extract | 25 mg |
| Akkermansia muciniphila | 20 mg |
| Trans-resveratrol | 10 mg |
Read against the advisory: the panel contains no vitamin D, no calcium, no vitamin B12, no protein in any meaningful amount, no magnesium and no fibre supplement as an active ingredient — none of the nutrients the four societies name. Its front-of-label words are "Metabolic health", "Triple-action formula" and "Time-release matrix", and it carries the standard notice that the statements "have not been evaluated by the Food and Drug Administration" and that the product "is not intended to diagnose, treat, cure or prevent any disease". The label directs use before the largest meals and asks people taking medication to consult their physician first.
That is not a finding about whether any single ingredient works — Akkermansia, for example, has one positive randomised result, discussed on GLP-1 supplements. It is a finding about the word: a product can be called a GLP-1 companion without containing any nutrient the GLP-1 nutrition guidance mentions.
The largest brand in the search data is not described here. Nature Made's GLP-1 companion line accounts for most of the searches on this subject, but its product pages refused automated requests on 19 November 2026 and the DSLD holds no record of it. Rather than describe its contents second-hand, this page leaves it out. The method above — the Supplement Facts panel read against the advisory's named nutrients — is the comparison that applies to it.
How to read a companion label
Four checks make any product in this category comparable:
- Does the panel contain the nutrients the advisory names — vitamin D, calcium, B12 — and in what amounts against the Daily Value?
- Is protein or fibre the point of the product, and how many grams per serving, set against what food provides?
- What is the claim? "Supports" and "helps maintain" are structure/function wording a supplement may use. Any suggestion that the product treats obesity, replaces the drug or reduces its side effects is a disease claim supplements are not allowed to make.
- Is there a trial of the product itself, rather than of one ingredient at a different dose?
The drug itself shapes some of this. Semaglutide and tirzepatide slow stomach emptying early in treatment, which is why the advisory's practical advice leans on food choices, meal size and fluids before supplements; see GLP-1 constipation and GLP-1 hair loss for those side-effect records.
What this page cannot tell you
- Whether any one person needs a supplement. The advisory frames that as an individual assessment with a clinician or registered dietitian, sometimes with blood tests.
- How often deficiencies occur on GLP-1s. No prospective study has measured it; the trial record mostly did not look.
- The contents of products whose labels could not be read, including Nature Made's.
Sources and dates
- Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity Pillars 2025;15:100181. doi:10.1016/j.obpill.2025.100181 (PMID 40673264; also in Am J Clin Nutr, Obesity and Am J Lifestyle Med; correction 2026, PMID 41962912). Full text read 19 November 2026.
- de Paulo RS, Bonifácio DB, de Carvalho MHL, Bressan J. Dietary strategies and nutritional management in patients receiving GLP-1 and dual GIP/GLP-1 receptor agonists: a systematic review of randomised clinical trials. Diabetes Obes Metab 2026;28(7):5492–5507. doi:10.1111/dom.70779. PMID 42037117 (abstract).
- Simancas-Racines D, et al. Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity. Obesity Pillars 2026;19:100290. doi:10.1016/j.obpill.2026.100290. PMID 42382663 (abstract).
- Bidesie J, Oudman E. Wernicke's encephalopathy following semaglutide treatment for obesity: a systematic PRISMA review of case-based evidence. Obesity 2026;34(Suppl 2):64–69. doi:10.1002/oby.70256. PMID 42399213 (abstract).
- NIH Office of Dietary Supplements, Dietary Supplement Label Database, label 333410 (Codeage GLP-Harmony Companion+, entered 24 July 2025) and a search for "GLP", both read 19 November 2026.
